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Abstract
The interactions between cancer cells and the extracellular
matrix (ECM) regulate cancer progression. The B1C and B1A
integrins, two cytoplasmic variants of the B1 integrin subfamily,
are differentially expressed in prostate cancer. Using gene
expression analysis, we show here that the B1C variant, an
inhibitor of cell proliferation, which is down-regulated in
prostate cancer, up-regulates insulin-like growth factor-II (IGF-
II) mRNA and protein levels. In contrast, B1A does not affect
IGF-II levels. We provide evidence that B1C-mediated up-
regulation of IGF-II levels increases adhesion to Laminin-1, a
basement membrane protein down-regulated in prostate
cancer, and that the B1C cytoplasmic domain contains the
structuralmotif sufficient to increase cell adhesion to Laminin-1.
This autocrine mechanism that locally supports cell adhesion
to Laminin-1 via IGF-II is selectively regulated by the B1 cyto-
plasmic domain via activation of the growth factor receptor
binding protein 2–associated binder-1/SH2-containing pro-
tein-tyrosine phosphatase 2/phosphatidylinositol 3-kinase
pathway. Thus, the concurrent local loss of B1C integrin, of its
ligand Laminin-1, and of IGF-II in the tumormicroenvironment
may promote prostate cancer cell invasion and metastasis by
reducing cancer cell adhesive properties. It is, therefore,
conceivable that reexpression of B1C will be sufficient to revert
a neoplastic phenotype to a nonproliferative and highly
adherent normal phenotype. (Cancer Res 2006; 66(1): 331-42)
Introduction
Prostate cancer cell interactions with the surrounding ECM
regulate their growth and metastasis (1). During prostate cancer
progression, disruption of basement membrane continuity as
well as synthesis of basement membrane proteins is observed
(2, 3). Fuchs et al. have shown a decrease in basement membrane
staining in high Gleason grade prostatic carcinoma and complete
absence of basement membrane in metastasis (4). Laminin-1
(composed of a1h1g1 subunits) is found in normal human prostate
glands (5–7) and in adult mouse prostate (8), but its expression
is lost in basement membrane surrounding primary carcinoma
and metastatic lymph node lesions (7). Laminin-1 is an important
component of the basement membrane and is involved in
epithelial cell adhesion and polarization (9). Mice that lack
Laminin-1 expression have been obtained by selective deletion
of the g1 chain. Laminin g1-null mice show a peri-implantation
lethal phenotype with failure of the embryos to survive beyond
E5.5 (10); as expected, g1-null embryos lack basement mem-
brane, a phenotype that resembles the alterations observed in
neoplastic tissues, where disruption of basement membrane
occurs (11).
Integrins are transmembrane ah heterodimeric receptors
that mediate cell adhesion to the ECM (12). By interacting with
the ECM, integrins transfer signals from the extracellular
environment to intracellular compartments and control many
cellular functions, such as proliferation, migration, differentiation,
and gene expression (12–14). Growth factor and chemokine
signaling have been reported to modulate integrin affinity, often
through phosphatidylinositol 3-kinase (PI3K) activation (15). In
mast cells, activation of PI3K by tyrosine kinase receptors, like
platelet-derived growth factor receptor, increases the affinity of
a5h1 (16). In metastatic breast cancer cells, increased cell adhesion
and migration upon stimulation of epidermal growth factor
receptor are also dependent on PI3K (17). In polymorphonuclear
leukocytes, PI3K modulates the activity of h3 integrin and thus
regulates their migration (18).
Among other integrins, h1 is typically the most abundant and
ubiquitously expressed subunit associated with a number of a
subunits to form distinct heterodimers (19). Targeted disruption of
the h1 integrin subunit, lethal to embryonic development, has
indicated a requirement for this receptor in the proper assembly
and subsequent function of embryonic basement membrane (20).
Integrin-mediated adhesion to ECM components as well as
integrin expression has been shown to alter the expression of
several gene products, through a variety of transcriptional,
translational and post-translational mechanisms. Among these
alterations, an increase in expression of immediate-early response
genes as well as different transcription factors in monocytes
responding to injury or infection (21), an increase in c-myc
protein levels in breast epithelial cells (22), a decrease in
intercellular adhesion molecule-1 expression in lung cancer cells
(23), the induction of matrix metalloproteinase gene expression
(24), and >32 genes differentially modulated in salivary epithelial
cells undergoing morphologic differentiation (25). Finally, expres-
sion of h1 variants per se has been shown to increase p21 mRNA
levels in hepatocellular carcinoma cells (26) or p27kip1 levels (27)
in several cell types and aVh3 expression in LNCaP prostate
cancer cells causes increased cdc2 mRNA, protein, and kinase
activity levels (28).
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h1 integrins exist in five different isoforms containing alterna-
tively spliced cytoplasmic domains (i.e., h1A, h1B, h1C, h1C-2, and
h1D). The h1C integrin contains a unique 48-amino-acid sequence in
its cytoplasmic domain (29). In vivo , h1C is expressed in non-
proliferative, differentiated epithelium and is selectively down-
regulated in prostatic carcinoma, and its expression inversely
correlates with markers of cell proliferation in breast carcinoma
(27, 30). The full-length h1C or its cytoplasmic domain alone, at
variance with h1A, has been shown to inhibit cell proliferation and
to increase cell adhesion to Laminin-1 (31). Preliminary evidence
indicated that h1C and h1A integrin expression can differentially
affect gene expression (32), thus suggesting that a selective
modulation of cellular functions by these cytoplasmic variants
could be attributed, at least in part, to a differential gene regulation.
Based on the hypothesis that variant sequences in the h1 integrin
cytoplasmic domain might modulate cancer cell functions through
regulation of gene expression, we have searched for genes differ-
entially expressed in h1C- and h1A-expressing cells by cDNA micro-
array analysis. We show here that expression of h1C, a cell cycle
inhibitor down-regulated in prostate cancer, up-regulates IGF-II
mRNA and protein levels. We provide evidence that up-regulation of
IGF-II expression by h1C integrinmediates increased cell adhesion to
Laminin-1 of h1C-expressing cells, through activation of a growth
factor receptor binding protein 2–associated binder-1 (Gab1)/SH2-
containing protein-tyrosine phosphatase 2 (Shp2)/PI3K–dependent
pathway.
Materials and Methods
Reagents and antibodies. Mouse Laminin-1, Lipofectin, Lipofect-
AMINE, and LipofectAMINE 2000 were purchased from Invitrogen
(Carlsbad, CA). Recombinant human IGF-I or IGF-II (rhIGF-II) was
purchased from R&D System, Inc. (Minneapolis, MN) or Austral Biologics
(San Ramon, CA), respectively. Human FN was purified as described (33).
Bovine serum albumin (BSA) was purchased from Sigma (St. Louis, MO).
Wortmannin was purchased from Calbiochem (La Jolla, CA).
The following monoclonal antibodies (mAbs) were used: to human h1
integrin P4C10 (Chemicon, Temecula, CA), clone-18 (BD Biosciences,
San Jose, CA), and TS2/16 [American Type Culture Collection (ATCC),
Manassas, VA]; to chicken h1 integrin W1B10 (Sigma Chemical Co., St.
Louis, MO); to human h4 integrin A9 (kindly provided by Dr. L. Shaw); to
hemagglutinin 12CA5 (ATCC); to a vascular endothelial surface protein
1C10 (Life Technologies, Inc., Gaithersburg, MD); to c-myc ; to h-tubulin
(Sigma). The following rabbit polyclonal antibodies were used: to IGF-I
receptor-h (IGF-IR-h), to extracellular signal-regulated kinase 1 and to Shp2
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA), to IGF-II (Peprotech, Inc.,
Rocky Hill, NJ), to phospho-Akt and to Akt (Cell Signaling, Beverly, MA).
Goat antibody to human IGF-II and nonimmune rabbit IgG (ni-IgG) were
purchased from Sigma. Purified mouse IgG (mIgG) was purchased from
Pierce (Rockford, IL).
Cell lines and transfectants. GD25 cells, which lack h1 integrin as a
consequence of gene inactivation (34, 35), were transfected with either
human h1A or h1C integrin under the control of a doxycycline-regulated
promoter (32). These cells were cultured in DMEM (Invitrogen) supple-
mented with 10% fetal bovine serum (FBS), 100 units/mL penicillin, 100 Ag/
mL streptomycin, 0.292 Ag/mL glutamine (all from Gemini Bio-Products,
Inc., Calabasas, CA), 250 Ag/mL amphotericin B (Sigma), and 150 Ag/mL
hygromycin (Roche, Indianapolis, IN).
Chinese hamster ovary (CHO) stable cell transfectants expressing either
human h1A or h1C integrin were cultured as described before (36). PC3
stable cell transfectants expressing chimeric h1A (clones 8 and 11) or h1C
(clones 17 and 19) integrin (chicken extracellular and human intracellular)
were generated using the tetracycline-regulated expression system and
cultured as described before (33). CHO-h1A, CHO-h1C, PC3-h1A, and PC3-
h1C clones were cultured for 48 hours in growth medium in the absence of
1 Ag/mL tetracycline to induce the expression of h1A or h1C integrin.
SV40-immortalized nontumorigenic human prostate epithelial cells, 267B1,
were cultured as described before (31).
Mouse embryo fibroblasts deficient for Gab1 (Gab1/) or reconstituted
with wild-type Gab1 (wt-Gab1) or empty vector [Gab1/ (Vector)] were
grown in DMEM supplemented with 10% FCS, 100 units of penicillin, and
100 Ag/mL streptomycin (37). Culture medium was supplemented with
300 Ag/mL hygromycin for Gab1/ (Vector) or wt-Gab1 cells.
3T3-immortalized fibroblast lines from Shp2 exon 3/(Shp2/) and
Shp2/ cells stably transfected with full-length wt-Shp2 cDNA (wt-Shp2)
were cultured in 10% FCS, 100 units of penicillin, and 100 Ag/mL
streptomycin (38).
Flow cytometry. Surface expression of exogenous human h1C or h1A
integrins in GD25 transfectants was achieved by addition of 2 Ag/mL
doxycycline (Clontech, Palo Alto, CA) in the growth medium; in both cell
transfectants, h1C or h1A expression was maximal at 24 hours after
doxycycline addition and was comparable in all the analyzed h1C or h1A
clones. In each experiment, exogenous human h1 integrin expression was
monitored in GD25 stable cell transfectants by fluorescence-activated cell
sorting (FACS) analysis using TS2/16 culture supernatant, or, as negative
control, 12CA5 culture supernatant (27). For the PC3 cell transfectants,
exogenous expression of the chimeric chicken/human h1 integrin was
monitored using W1B10 or, as negative control, mIgG. Surface expression of
endogenous h4 integrin in 267B1 cells was detected by FACS analysis using
A9 or, as negative control, mIgG (1 Ag/mL).
RNA isolation and analysis. Gene expression profiles of h1A-GD25 or
h1C-GD25 stable cell transfectants were generated using 1.2 Atlas Mouse
cDNA Expression Arrays (Clontech) according to the manufacturer’s
instructions. GD25 stable cell lines were starved for 48 hours. During the
last 24 hours, cells were kept in the presence of 2 Ag/mL doxycycline and
then detached using 0.05% trypsin/0.53 mmol/L EDTA. Cells were washed
and plated for 5 hours at 37jC (3-5  106 per plate) on fibronectin (5 Ag/
mL). Attached cells were cultured for 8 hours at 37jC in growth medium
containing 10% FBS in the presence of 2 Ag/mL doxycycline and then
trypsinized and washed. mRNA was isolated and labeled with [a-32P]dATP
(Amersham, Arlington Heights, IL) using the Atlas Pure Total RNA Labeling
System (Clontech) according to the manufacturer’s instructions. 32P-labeled
cDNA probes were synthesized from a mixture of mRNAs containing equal
amounts of mRNAs prepared using either three h1C-GD25 clones or three
h1A-GD25 clones and hybridized to Clontech’s 1.2 Atlas Mouse cDNA
Expression Arrays. Following hybridization and washing, the arrays were
visualized and quantitated using a PhosphorImager and ImageQuant
software (Molecular Dynamics, Sunnyvale, CA).
Northern blot analysis was done using total RNA isolated from cells kept
in the same conditions described above for the array analysis and cultured
on fibronectin in the presence or absence of 2 Ag/mL doxycycline for 5
hours and in the presence or absence of 10% FBS for 8 and 12 hours. Total
RNA (10 Ag), isolated using TRIzol Reagent (Life Technologies), was
electrophoresed through a 1.5% denaturing agarose gel containing 660
mmol/L formaldehyde and transferred to a nylon membrane (Hybond N+,
Amersham). The filters were subsequently prehybridized for 4 hours at 42jC
with a buffer consisting of 50% formamide, 5 Denhardt’s solution (0.1%
Ficoll 400, 0.1% polyvynilpirrolidone, 0.1% BSA), 5 SSC [0.75 mol/L NaCl,
0.075 mol/L Na citrate (pH 7.0)], 0.5% SDS, and 100 Ag/mL sonicated
salmon sperm DNA. Filters were then hybridized for 16 to 20 hours at 42jC
by adding 3 to 4  106 cpm of 32P-labeled probe/mL to the prehybridization
solution. The filters were washed once with 2 SSC, 0.1% SDS for 10
minutes at room temperature, then with 1 SSC, 0.1% SDS at 42jC,
followed by several washes in 0.2 SSC, 0.1% SDS at 55jC. Bands were
visualized by exposing the filters in a Phosphorimager and/or by
autoradiography. The IGF-II probe was generated from a 1.4-kb EcoRI
restriction fragment excised from a murine preproIGFII cDNA clone (39)
and purified from agarose gels using QIAEX II Gel Extraction Kit (Qiagen,
Inc., Valencia, CA). The glyceraldehyde 3-phosphate deydrogenase (GAPDH)
probe was generated from pGEM3zf(+) containing a 780-bp human GAPDH
cDNA. Probe radiolabeling was done using the Random Primed DNA
Cancer Research
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Labeling Kit (Boehringer Mannheim GmbH, Indianapolis, IN) and
[a-32P]dCTP (3,000 Ci/mmol; NEN, Boston, MA) followed by Sephadex
G-50 spin-column chromatography (QuickSpin Columns, Boehringer
Mannheim). Quantitative analysis was done using a computing densitom-
eter (Molecular Dynamics) and ImageQuant software.
Immunoblotting. IGF-II was quantitated in cell lysate or in the culture
medium by immunoblotting analysis. GD25 stable cell transfectants were
starved for 48 hours. During the last 24 hours, cells were kept either in
presence or absence of 2 Ag/mL doxycycline and then detached using 0.05%
trypsin/0.53 mmol/L EDTA. Cells were washed and plated for 5 hours at
37jC (3-5  106 per plate) on fibronectin (5 Ag/mL). Attached cells were
cultured for 12 hours at 37jC in growth medium containing 10% FBS either
in the presence or absence of 2 Ag/mL doxycycline and then trypsinized,
washed, and lysed. In some experiments, GD25 stable cell transfectants
were neither starved nor plated on fibronectin and were kept either in
presence or absence of 2 Ag/mL doxycycline for 36 hours in growth medium
containing 10% FBS. CHO stable cell transfectants were kept either in the
presence or absence of 1 Ag/mL tetracycline for 48 hours, trypsinized,
washed, and lysed. In all the experiments using lysates, the following lysis
buffer was used: 0.5% SDS, 20 mmol/L Tris (pH 8.0). The protein content of
each lysate was quantified using the bicinchoninic acid protein assay
reagent (Pierce). For analysis of IGF-II in the culture medium, IGF-II was
separated from binding proteins by acidification followed by ultrafiltration
as previously described (39). To each gel track, a volume of culture medium
equivalent to 2  106 cells was loaded. Cell protein extract (100 Ag) or
ultrafiltered culture medium was separated by 15% SDS-PAGE under
nonreducing conditions and transferred onto polyvinylidene fluoride
membranes (Immobilon-P, Millipore, Bedford, MA) at 4jC. The membrane
was blocked with blocking buffer [TBS-T: 20 mmol/L Tris (pH 7.5), 150
mmol/L NaCl, 0.1 % Tween 20, plus 5% dry milk] for 1 hour at room
temperature and immunoblotted with either 0.2 Ag/mL rabbit purified
antibody to IGF-II or a 1:500 dilution of mAb to h-tubulin. As negative
control, 0.2 Ag/mL ni-IgG was used.
CHO cells were detached 48 hours after transient transfection with
either vector alone (pcDNA3) or wt p110 (pSG5-p110 wt) or constitutive
active p110 (pSG5-p110 c.a.) myc-tagged constructs, washed, and lysed in
20 mmol/L Tris (pH 7.5), 150 mmol/L NaCl, 10% glycerol, 1% NP40,
10 mmol/L NaF, 1 mmol/L NaVO4, 1 mmol/L Na4O7P2, 2 Amol/L leupeptin,
2 Amol/L aprotinin, 1 mmol/L phenylmethylsulfonyl fluoride. Proteins
(50 Ag) were separated by 10% SDS-PAGE under reducing conditions and
immunoblotted with either 2 Ag/mL mAb to c-Myc or a 1:500 dilution of
mAb to h-tubulin.
h1C-CHO (C11) and h1A-CHO (A11) cells were cultured in the absence of
tetracycline. After 36 hours, cells were incubated for 30 minutes at 37jC in
the presence or absence of wortmannin (0 and 50 nmol/L) or the solvent
alone (Me2SO). Cells were lysed, and proteins were immunoblotted with an
antibody to phospho-Akt or to Akt, as a loading control.
IGF-II detection by ELISA. PC3 cells stably transfected with h1A or h1C
integrin under the control of tetracycline-regulated promoter were
induced to express exogenous integrins, and culture supernantants were
collected. The culture supernatants were concentrated using centricon
filters. IGF-II protein levels in the culture supernatants were measured by
ELISA for IGF-II (Diagnostic System Laboratories, Webster, TX) as per
manufacturer’s instructions.
Transient transfection. PC3 cells were transiently transfected with
pCMV-h-galactosidase (h-gal, 2 Ag), Ch1h1A (20 Ag), or Chh1C (20 Ag)
chimeric constructs (extracellular CD4 and intracellular h1 integrin)
described before (40). Gab1/, Gab1/ (Vector), wt-Gab1, Shp2/, or
wt-Shp2 cells were transiently transfected with h-gal (2 Ag) and either
pBJ1 (20 Ag), pBJ1-h1C (20 Ag), or pBJ1-h1A (20 Ag) cDNA. h1A-CHO and
h1C-CHO clones were transiently transfected with h-gal (2 Ag) and either
vector alone (pLXSN), pLXSN-wt-Gab1 or pLXSN-DShp2-Gab1, as
described before (41). Cells were cultured in the absence of tetracycline
in growth medium for 48 hours. Cells were harvested 48 hours after
transfection and used in adhesion assays as described below. In parallel,
transfected cells were seeded on 48-well plates and stained for h-gal
expression to determine transfection efficiency as described (28). All
abovementioned transient transfections were done using LipofectAMINE
2000 according to the manufacturer’s instructions.
Myc-tagged cDNAs containing constitutively active PI3K (pSG5-p110 c.a.)
or the wt PI3K p110 catalytic subunit (pSG5-p110 wt) were a generous gift of
Dr. Downward. Cells were transfected with 1 Ag h-gal along with 1 Ag of
either one of the PI3K variant cDNAs or a vector alone using LipofectAMINE
according to the manufacturer’s instructions. Cells were harvested 48 hours
after transfection and used in adhesion assays as described below. Trans-
fected cells were also plated in 48-well plates to stain for h-gal expression to
determine transfection efficiency. The h-gal staining was done as described
previously (28).
Cell adhesion assay. PC3 stable cell transfectants or 267B1 cells were
serum-starved overnight, detached, and then allowed to adhere to Laminin-
1, BSA (100 Ag/mL), fibronectin (3 Ag/mL), or an antibody to h3 integrin
(AP3, culture supernatant, 1:10 dilution) for 2 hours at 37jC in the presence
or absence of IGF-I (100 ng/mL). Cells were fixed and stained with crystal
violet (0.5%), and absorbance was measured at 630 nm (28). Where
specified, cells were incubated with either blocking mAb to h1, P4C10, or as
negative control, mIgG (1 Ag/mL) for 1 hour on ice.
CHO cell adhesion to Laminin-1 was done as described (42) by
incubating 25,000 51Cr (DuPont NEN, Wilmington, DE)–labeled cells with
the coated substrates for 2 hours at 37jC in the presence or absence of
IGF-II (100 ng/mL). Where specified, cells were incubated with either rabbit
affinity-purified antibody to IGF-II or, as negative control, ni-IgG (0.1 Ag/
mL) for 1 hour on ice. Where indicated, 51Cr-labeled cells were incubated
for 30 minutes at 37 jC either in the presence or absence of wortmannin
(at the concentrations indicated in the figure) or DMSO (Me2SO). Adhesion
of CHO cells to Laminin-1 (100 Ag/mL), fibronectin (3 Ag/mL), or BSA
(100 Ag/mL) after being transiently transfected with vector alone (pcDNA3),
or p110 cDNA constructs was done by incubating 150,000 cells with the
coated substrates for 2 hours at 37jC. After adhesion, h-gal-positive and
h-gal-negative cells were counted, the attached cells were washed once
with PBS and stained with 0.5% toluidine blue (Sigma), and the absorbance
at 630 nm was determined. Triplicate observations were done in each
experiment.
Alternatively, cell adhesion assays of PC3, Gab1/, Gab1/ (Vector),
wt-Gab1, CHO stable cell transfectants, Shp2/, wt-Shp2, GD25, or h1A-
GD25 cells to BSA, Laminin-1 (100 Ag/mL), or fibronectin (10 Ag/mL) after
being transiently transfected with cDNA constructs were done by
incubating cells with the coated substrates for 2 hours at 37jC in the
presence or absence of IGF-II or IGF-I (100 ng/mL). After adhesion, h-gal
staining was done and h-gal-positive and h-gal-negative cells were
counted, the attached cells were washed and stained with 0.5% toluidine
blue, and the absorbance at 630 nm was determined. Where specified,
cells were incubated with either P4C10 or as negative control 1C10 as
described above.
Analysis of IGF-IR association with Shp2. CHO clones were induced
to express h1A or h1C integrin. Cells were stimulated with IGF-I (100 ng/
mL) for 10 minutes, washed, and lysed. Proteins were immunoprecipi-
tated by incubating with an antibody to IGF-IR and protein A-Sepharose
as described (31). Immunocomplexes were separated by 7% SDS-PAGE
and immunoblotted using antibodies to IGF-IR-h (0.2 Ag/mL) or to Shp2
(0.2 Ag/mL).
Statistical analysis. Statistical analysis was done using the Student’s t
test. All experiments were repeated at least twice.
Results
B1C integrin expression increases IGF-II mRNA levels. To
identify specific genes that are regulated by h1 integrin
cytoplasmic variants, cDNA expression array analysis was done
using stably transfected mouse GD25 cells expressing either
human h1C or h1A integrin cDNAs, under the control of a
doxycycline-regulated promoter (32). GD25 stable cell trans-
fectants were starved for 48 hours and induced for the last 24
hours with doxycycline. Comparable levels of surface expression
Integrin Regulation of IGF-II Expression
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of h1C and h1A were consistently obtained in all the experiments,
24 hours after doxycycline addition (Fig. 1A); exogenous ex-
pression of either h1C or h1A was undetectable in the absence of
doxycycline (Fig. 1A ). Twenty-four hours after doxycycline
addition, GD25 stable cell transfectants were allowed to attach
to fibronectin for 5 hours, stimulated by 10% FBS for additional
8 hours, processed for mRNA extraction, and analyzed for
differential gene expression. Sixteen of 1,176 genes were found
to be differentially regulated in h1C- and h1A-expressing cells
(data not shown). Among these genes, IGF-II showed the highest
remarkable difference in expression between h1C- and h1A-
expressing cells (8.7-fold increase in h1C versus h1A cells;
Fig. 1B). The surface expression levels of h1C and h1A integrins
were comparable at the time when the cells were processed for
cDNA expression array analysis (data not shown). The results
obtained using the cDNA array screening were confirmed by
Northern blot hybridization (Fig. 1C) of total RNA extracted from
three h1C-GD25 clones and three h1A-GD25 clones kept in culture
as described for the cDNA array analysis, either in the presence or
absence of doxycycline and in the presence of 10% FBS for 8 and
12 hours. Northern blot hybridization with a 32P-labeled (prepro)
IGF-II cDNA probe detected predominantly two IGF-II transcripts
at f3.7 and f1.7 kb, both in h1C-GD25 and h1A-GD25 cells. Both
transcripts were weakly expressed in either induced (+ dox) or
noninduced ( dox) h1A-GD25 cells. In contrast, both transcripts
were found to be up-regulated at 8 and 12 hours after addition of
10% FBS in h1C-GD25–induced cells (+ dox) compared with cells
that had not been induced ( dox). Maximal levels of IGF-II were
detected at 12 hours; for C1, C2, and C3 clones, 6.2-, 5.9-, and 8.9-
fold increase for the 3.7-kb mRNA and 6.5-, 7.1-, and 9.8- fold
Figure 1. h1C integrin expression increases IGF-II mRNA levels. A-C, h1C-GD25 and h1A-GD25 stable cell transfectants were starved for 48 hours. During the last
24 hours, cells were kept in the presence (A and C: + dox ; B ) or absence (A and C :  dox ) of 2 Ag/ml doxycycline and then detached, resuspended in serum-free
medium, and processed for FACS analysis (A) and for either cDNA Array expression analysis (B) or Northern blotting analysis (C ). A, FACS analysis of surface
expressed h1 integrins was done using TS2/16 mAb (gray line ) to human h1 integrin followed by FITC-goat anti-mouse IgG. 12CA5 (black line ) was used as a negative
control. Fluorescence intensity is expressed in arbitrary units. FACS analysis of a representative clone for each h1 variant. B, cells were plated on 5 Ag/mL fibronectin,
and attached cells were cultured for additional 8 hours in the presence of 10% FBS and 2 Ag/mL doxycycline. The cells were then detached and processed for cDNA
expression array analysis. 32P-labeled first-strand cDNA probes prepared with a 1:1:1 mixture of mRNAs isolated from either three h1C-GD25 clones (C1, C2, and C3;
left) or three h1A-GD25 clones (A1, A2, and A3; right ) were hybridized to Clontech’s 1.2 Atlas Mouse cDNA Expression Arrays. Sections (D) of one cDNA array
membrane. Similar results were obtained using another pair of array membranes hybridized using the same 32P-labeled cDNA in the same experiment (data not shown)
and in two separate experiments. Arrow, spot corresponding to IGF-II cDNA on the array. C, total RNA (10 Ag) was isolated from h1C-GD25 cells (clones C1, C2, and
C3) and h1A-GD25 cells (clones A1, A2, and A3) grown as described in (B ), in the presence of 10% FBS for 8 and 12 hours after adhesion to fibronectin (5 Ag/mL)
and either in the presence or absence of 2 Ag/mL doxycycline. Total RNA was fractionated by agarose-formaldehyde gel electrophoresis, transferred to Hybond N+
membranes, and hybridized using a 1.4-kb IGF-II cDNA probe, the probe specifically recognized two bands of 3.7 and 1.7 kb. GAPDH cDNA probe was used as
a control for RNA loading.
Cancer Research
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increase for the 1.7-kb mRNA were observed, respectively. These
results show that IGF-II mRNA is specifically up-regulated in h1C-
expressing cells.
B1C integrin expression up-regulates IGF-II protein levels.
To evaluate whether the increase in IGF-II mRNA levels in
h1C-expressing cells caused an increase in IGF-II protein levels,
immunoblotting analysis was done. Cell lysates were prepared
from GD25 stable cell transfectants attached to fibronectin and
stimulated by FBS for 12 hours, as described above for the
Northern blotting analysis. As shown in Fig. 2A , IGF-II protein
levels were increased in GD25 cells after h1C expression but not
after h1A expression by two different antibodies to IGF-II but not
by ni-IgG as negative control (Fig. 2A ; data not shown). To
investigate a possible contribution of h1 integrin engagement by
Figure 2. IGF-II protein levels are increased in h1C-expressing GD25
and CHO cells, which mediate cell adhesion to laminin-1. A, h1C-GD25
(clones C1, C2, and C3) and h1A-GD25 (clones A1, A2, and A3) stable cell
transfectants were starved for 48 hours. During the last 24 hours, cells were
kept either in the presence or absence of 2 Ag/mL doxycycline (dox ) and then
detached, resuspended in serum-free medium, and plated on fibronectin
(5 Ag/mL) for 5 hours. Attached cells were cultured for additional 12 hours
in growth medium containing 10% FBS in the presence (+dox ) or absence
(dox ) of 2 Ag/mL doxycycline. Cells were then detached, washed, and
lysed, with IGF-II protein levels evaluated by immunoblotting using 0.2 Ag/mL
purified rabbit antibody to IGF-II (top ). B, h1C-GD25 (clones C1 and C2),
h1A-GD25 (clones A1 and A2), h1C-CHO (clones C11 and C12), and
h1A-CHO (clones A11 and A12) stable cell transfectants were cultured
either for 36 hours in the presence (+dox ) or absence (dox ) of 2 Ag/mL
doxycycline (GD25 cells), or for 48 hours in the presence (+tet ) or absence
(tet ) of 1 Ag/mL tetracycline (CHO cells), and then detached, washed, and
lysed, with IGF-II protein levels (top ) evaluated as described in (A). A and B,
mAb to tubulin (a-tubulin ) was used to control for protein loading (bottom ).
C, h1C-GD25 (clone C2), h1A-GD25 (clone A1), h1C-CHO (clone C11), and
h1A-CHO (clone A12) stable cell transfectants were grown as described
in (B), and culture supernatants were collected and processed for IGF-II
analysis as described in Materials and Methods. rhIGF-II (20 ng) was used as
positive control. Proteins were visualized by enhanced chemiluminescence.
D, h1C-CHO cells (clone C11) and h1A-CHO cells (clone A11) were cultured
for 48 hours either in the presence or in the absence of 1 Ag/mL tetracycline.
Cells (2.5  104) were labeled using [51Cr]sodium chromate. [51Cr]-labeled
cells were incubated for 1 hour on ice either in the presence or absence of
purified rabbit antibody to IGF-II or ni-IgG (1 Ag/mL) as negative control and
then allowed to adhere to laminin-1 (100 Ag/mL) at 37jC for 2 hours.
% Attached cells, taking as 100% the number of cells adherent to laminin-1
for each clone expressing the h1 integrin variant (tet), in the absence of
antibody. One representative clone for each h1 variant. The differences
between h1C-CHO cell adhesion to laminin-1 either in the presence or
absence of the antibody to IGF-II are statistically significant. *, P < 0.001.
Consistent results were obtained with another clone for both the h1 variants
from at least two separate experiments. Columns, mean; bars, SD.
, h1C-CHO (C11); , h1A-CHO (A11).
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fibronectin on h1C-induced expression of IGF-II, an immuno-
blotting analysis was done using lysates from cells that had not
been plated on fibronectin; for these assays, the cells were
seeded either in the presence or in the absence of doxycycline
for 36 hours. As shown in Fig. 2B (top two), IGF-II was detected
only in h1C-GD25 cells, showing that up-regulation of IGF-II
protein levels occurred also in the absence of h1 integrin
engagement by fibronectin. To investigate whether regulation of
IGF-II protein levels by h1C integrin occurred also in cells that
coexpress h1C and h1A integrin, immunoblotting analysis was
done using CHO cell lysates known to express an endogenous
h1A integrin and stably transfected with either human h1C or h1A
integrin cDNA under the control of tetracycline-regulated
promoter (Fig. 2B , bottom two). In these stable cell transfectants,
removal of tetracycline induced expression of the exogenous
h1 integrins (36). As shown in Fig. 2B , an increase in IGF-II
protein levels was observed in h1C-expressing cells compared
with h1A-expressing CHO cells (3.13 F 0.37-fold increase for
clone C11 and 1.97 F 0.47-fold increase for clone C12 in two
independent experiments). IGF-II was found secreted in the
extracellular medium of h1C- but not h1A-expressing GD25 and
CHO stable cell transfectants (Fig. 2C). Overall, these results
show that the h1C integrin up-regulates IGF-II protein levels
both in the presence or absence of endogenous h1A integrin.
IGF-II mediates B1C-CHO cell adhesion to Laminin-1. In our
previous study, we have shown that h1C integrin expression
increases cell adhesion to Laminin-1 (31). As shown in Fig. 2D
(top), h1C-mediated cell adhesion to Laminin-1 was prevented by
addition of an antibody raised against the soluble form of IGF-II
(77.7 F 7.0% inhibition versus adhesion in the absence of
antibody, in two independent experiments using two different
clones). The slight decrease observed in presence of ni-IgG was
Figure 3. IGF-II protein levels are increased in h1C-expressing PC3 cells. A-B, h1C-PC3 (clone 17) and h1A-PC3 (clone 8) cells were cultured for 72 hours either in
the presence (+tet ) or absence (tet) of 1 Ag/mL tetracycline. A, FACS analysis for surface expressed h1 chimeric human/chicken integrin was done using W1B10
mAb to chicken h1 integrin (solid line ) followed by FITC-goat anti-mouse IgG. mIgG (dotted line ) were used as a negative control. B, IGF-II protein levels were evaluated
in h1C-PC3 and h1A-PC3 cell culture supernatant by ELISA. C-D, h1C-PC3 and h1A-PC3 clones were cultured in the absence of tetracycline in growth medium for
48 hours. Cells were incubated in the presence of purified mouse blocking antibody to h1 integrin (P4C10) or mIgG for 1 hour on ice. Cells were plated on BSA or
laminin-1 (C ) or antibody to h3 integrin (AP3), as a loading control (D ) at 37jC for 2 hours in the presence or in the absence of IGF-I. Attached cells were washed, and
cell adhesion was analyzed by crystal violet staining. Experiments were repeated at least twice with similar results. Columns, mean; bars, SE. C, differences in cell
adhesion to laminin-1 in the presence or absence of blocking antibody to h1 integrin (P4C10) of h1C-expressing cells are statistically significant. *, P V 0.01; **, P V 0.001.
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not reproducible in subsequent experiments. No inhibition of cell
adhesion to Laminin-1 was observed in h1A-CHO cells either in
the presence or in the absence of tetracycline (Fig. 2D, bottom).
These data show that IGF-II mediates h1C integrin-dependent cell
adhesion to Laminin-1.
IGF-II protein levels are increased in B1C-expressing PC3
cells. Because the h1C integrin is down-regulated during prostate
cancer progression (43), we analyzed the ability of h1C to regulate
IGF-II protein expression in PC3 prostate cancer cells stably
transfected with h1C or h1A integrin under the control of a
tetracycline-regulated promoter (31, 33). Expression of exogenous
h1C andh1A integrin was similar in PC3 stable transfectants (Fig. 3A).
IGF-II was detectable only in h1C but not in h1A-expressing PC3 cell
culture supernatant (Fig. 3B).
Both IGF-I and IGF-II are known to bind IGF-IR (44) and
stimulate adhesion to Laminin-1 of PC3 cells expressing h1C (31).
As expected, h1C expression increased cell adhesion to Laminin-1,
and this effect was further enhanced by exogenous addition of
IGF-I (Fig. 3C). As shown in Fig. 3C , IGF-I stimulated adhesion to
Laminin-1 of cells expressing h1C in the presence of mIgG but not
in the presence of P4C10, an inhibitory antibody to h1. The
differences in adhesion between h1C-expressing cells attached to
Laminin-1 in the presence of P4C10 and h1C- expressing cells
attached to BSA were not statistically significant. P4C10 had no
effect on cell adhesion to AP3, an antibody to h3 integrin (Fig. 3D).
Although prostate epithelial cells express the h4 integrin, known to
bind Laminin-5 as well as Laminin-1 (5), this integrin did not seem
to play a role in IGF-stimulated cell adhesion to Laminin-1. Cell
adhesion to Laminin-1 of nontumorigenic prostate epithelial cells,
267B1, which do express h4 integrin (Fig. 4A) and h1C integrin (40),
was completely prevented by P4C10, an antibody to h1 integrins. As
shown in Fig. 4B , IGF-I promoted adhesion in the presence of mIgG
but not in the presence of P4C10. P4C10 had no effect on 267B1 cell
adhesion to AP3, an antibody to h3 integrin. Overall, these results
show that h1C expression contributes to cell adhesion to Laminin-1
via IGF-II, although this effect is not maximal and does not prevent
an additional response to IGF-I.
Expression of the B1C cytoplasmic domain is sufficient to
promote cell adhesion to Laminin-1. To study the role of the h1C
integrin cytodomain in cell adhesion to Laminin-1, we transiently
transfected Chh1C or Ch1h1A chimera or vector alone in PC3 cells.
We found that the h1C but not the h1A integrin cytodomain has the
ability to increase cell adhesion to Laminin-1 (Fig. 5). This effect was
further enhanced by addition of exogenous IGF-I. There was no
effect on cell adhesion to fibronectin. In conclusion, the h1C
cytodomain regulates the ability of endogenous h1 integrins to bind
to Laminin-1.
Gab1-Shp2 interaction is required for adhesion to Laminin-
1 of B1C expressing cells. As previously shown, Gab1 binds h1C
but not h1A, and its tyrosine phosphorylation is increased in cells
Figure 4. h1 mediates IGF-stimulated cell adhesion to laminin-1. A, FACS
analysis for surface expressed h4 integrin was done using A9 mAb to human
h4 integrin (solid line ) followed by FITC-goat anti-mouse IgG. mIgG (gray filled )
were used as a negative control. B, 267B1 cells were incubated in the presence
of purified mouse blocking antibody to h1 integrin (P4C10) or mIgG for 1 hour on
ice. Cells were plated on BSA or laminin-1 (LN-1 ) or antibody to h3 integrin
(AP3), as a loading control at 37jC for 2 hours in the presence or absence of
IGF-I. Attached cells were washed, and cell adhesion was analyzed by crystal
violet staining. Columns, mean; bars, SE.
Figure 5. The h1C cytoplasmic domain is sufficient
to promote IGF-I-mediated cell adhesion to laminin-1.
PC3 cells were transiently transfected with CD4-h1A
(Ch1h1A), CD4-h1C (Chh1C), or Vector alone and
cultured for 48 hours. Cells (80,000 per well) were
plated on BSA, laminin-1 (LN-1 ), or fibronectin
(FN)–coated 96-well plate in the presence or absence
of IGF-I (100 ng/mL) and incubated for 2 hours at 37jC.
After incubation, cells were fixed and stained for h-gal
expression. Attachment of cells transfected with
Ch1h1A, Chh1C, or Vector alone were expressed as
percentage of the number of attached cells transfected
with CD4-h1A attached to laminin-1 in the absence of
IGF-I, set at 100. Experiments were repeated at least
twice with similar results. Columns, mean; bars, SE.
Differences in cell adhesion to laminin-1 between
Ch1h1A and Chh1C either in the presence or in the
absence of IGF-I are statistically significant. *, P V 0.01;
**, P V 0.001.
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expressing h1C compared with cells expressing h1A (31). To
analyze the role of Gab1 in adhesion to Laminin-1 of cells
expressing h1C, we used Gab1-null cells (Gab1
/) or Gab1null
cells retransfected with either vector [(Gab1/ (Vector)] or wt-
Gab1. As shown in Fig. 6A , h1C expressing cells showed increase
adhesion to Laminin-1 only in the presence of wt-Gab1
expression; however, h1C did not increase adhesion to Laminin-
1 of Gab1-null cells, suggesting an important role for Gab1 in cell
adhesion to Laminin-1. Because Gab1-null cells attached to
fibronectin as well as cells expressing wt-Gab1, these results show
that Gab1 role is specific for Laminin-1 (Fig. 6B).
We have shown previously that h1C integrin expression inhibits
tyrosine phosphorylation of IGF-IR (31); this resulted in an
inhibition of proliferative and tumorigenic signals activated by
IGF-IR but in an increase of cell adhesion to Laminin-1 (31). One
of the potential mechanisms by which h1C integrin supports
cell adhesion to Laminin-1, is by recruiting Shp2 via Gab1 to
IGF-IR, resulting in dephosphorylation of IGF-IR. To study this
hypothesis, we transiently transfected the h1C or h1A expressing
cells with wt-Gab1, DShp2-Gab1 (Gab1 mutant which has lost the
ability to bind Shp2) or vector alone. h1C-expressing cells showed
increased adhesion to Laminin-1 in the presence of wt-Gab1, but
not of DShp2-Gab1 expression (Fig. 6C). Gab1-Shp2 interactions
did not affect cell adhesion to fibronectin (Fig. 6D). These data
show that Gab1-Shp2 interaction plays an important role in
cell adhesion to Laminin-1. To study the effect of h1C integrin
Figure 6. Gab1-Shp2 interaction is required for IGF-I-stimulated adhesion to laminin-1 of h1C-expressing cells. A-B, Gab1
/ cells, Gab1/ cells retransfected
with either empty vector or wt-Gab1 were transiently transfected with vector alone or human h1A or h1C. Cells were detached and seeded on BSA or laminin-1 (A )
or fibronectin-coated (B) 96-well plates at 37jC for 2 hours in the presence of IGF-I and stained with h-gal. Cell adhesion was expressed as percentage of attached
Gab1/ (Vector) cells transfected with pBJ-h1A, set at 100. A, differences in cell adhesion to laminin-1 between pBJ-h1A or pBJ-h1C cDNA transfected
wt-Gab1-expressing MEF cells in the presence of IGF-I are statistically significant (*, P V 0.001). The experiments were repeated at least twice with similar results.
Columns, mean; bars, SE. C-D, h1A-CHO and h1C-CHO clones were transiently transfected with vector alone, wt-Gab1, or DShp2-Gab1. Cells were cultured in
the absence of tetracycline in growth medium for 48 hours. Cells were plated on either laminin-1 (C ) or fibronectin (D ) and incubated for 2 hours at 37jC in the
presence of IGF-I. After incubation, cells were fixed and stained with h-gal. Attachment of cells was expressed as percentage of the number of attached h1A-CHO cells
transfected with vector alone, set at 100 in the presence of IGF-I. C, differences in cell adhesion to laminin-1 between h1A-expressing or h1C-expressing CHO cells
transfected with vector alone or wt-Gab1 in the presence of IGF-I are statistically significant. *, P V 0.04. E, h1A-CHO and h1C-CHO clones were cultured in the absence
of tetracycline in growth medium for 48 hours, stimulated with or without IGF-I (100 ng/ml), and lysed, and IGF-IR was immunoprecipitated using an antibody to
IGF-IR-h. The immunoprecipitates were separated on SDS-PAGE and immunoblotted with an antibody to Shp2 or IGF-IR-h. Fold increase obtained using densitometric
analysis upon normalization. The experiments were repeated at least three times with similar results.
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expression on the recruitment of Shp2 to IGF-IR, we analyzed the
association between Shp2 and IGF-IR by coimmunoprecipitation
assay. As shown in Fig. 6E , expression of h1C integrin increased the
recruitment of Shp2 to IGF-IR. We also found that expression
of DShp2-Gab1 partially rescued (30%) h1C-mediated inhibition
of cell proliferation (data not shown), suggesting that this
mechanism contributes to h1C - mediated antiproliferative effect.
To confirm the role of Shp2, we used Shp2-null cells (Shp2/)
or Shp2-null cells retransfected with wt-Shp2 (Wt-Shp2). As shown
in Fig. 7A , h1C integrin increased adhesion to Laminin-1 of cells
expressing wt-Shp2, suggesting an important role for Shp2 in cell
adhesion to Laminin-1. Shp2-null cells attached to fibronectin as
well as cells expressing wt-Shp2, suggesting that Shp2’s role is
specific to Laminin-1 (Fig. 7B). From these results, we conclude
that Gab1-Shp2 interaction is required for adhesion to Laminin-1
of h1C-expressing cells.
PI3K regulates B1 integrin-mediated cell adhesion to
Laminin-1. We have previously reported that PI3K is involved in
IGF-I-stimulated adhesion to Laminin-1 in the presence of h1C
expression (31). To investigate whether PI3K, a signaling molecule
known to be activated by integrins as well as by growth factor
receptors (45), was involved in h1C-mediated cell adhesion to
Laminin-1, adhesion assays were done in CHO stable cell trans-
fectants in the presence of wortmannin, an inhibitor of PI3K. As
shown in Fig. 8A-B , wortmannin inhibited PI3K activation,
measured by Akt phosphorylation, as well as adhesion to
Laminin-1 of h1C-expressing cells, but had no effect on h1A-
expressing cells. The inhibitory effect of wortmannin was specific
for Laminin-1 because adhesion to fibronectin was not affected
(data not shown). The evidence that h1C integrin promoted cell
adhesion to Laminin-1 by enhancing the activity of PI3K suggested
that expression of a constitutively active form of PI3K in h1A-stable
cell transfectants should increase their adhesion to Laminin-1.
To validate this hypothesis, a myc-tagged constitutively active (c.a.)
form of the PI3K p110 catalytic subunit (myc-p110 c.a.; ref. 46) was
transiently expressed in h1A-CHO stable cell transfectants, and the
ability of these cells to adhere to Laminin-1 was compared with
cells transfected with an empty vector or with a myc-tagged wild-
type form of the PI3K p110 catalytic subunit (myc-p110 wt). As
shown in Fig. 8C , c.a. PI3K increased cell adhesion to Laminin-1 of
3.29F 0.63 fold in h1A-CHO stable cell transfectants. There were no
significant differences between cells transfected with either vector
alone or wild-type PI3K.
To investigate whether PI3K activation was the limiting step for
adhesion to Laminin-1 of h1A-expressing cells, h1A or h1-null GD25
cells were transiently transfected with either vector alone or myc-
p110 c.a cDNAs and plated on Laminin-1 (Fig. 8D). Adhesion of
h1A-GD25 cells to Laminin-1 was increased upon expression of
p110 c.a. To prove specificity, h1A-GD25 cells, transfected with p110
c.a., were incubated with P4C10, a blocking Ab for h1 integrins and
analyzed for their ability to adhere to Laminin-1. Incubation with
P4C10 prevented adhesion to Laminin-1 (Fig. 8D), thus confirming
that the increase in adhesion to Laminin-1 upon expression of p110
c.a in h1A-GD25 cells is mediated by the h1A integrin. Overall, these
results show that PI3K activation is the limiting step for h1A
integrin-mediated cell adhesion to Laminin-1.
Discussion
This study shows that h1 integrins, via an autocrine loop that
involves IGF-II, modulate cancer cell adhesion to basement
membrane proteins. Specifically, we provide evidence that
exogenous expression of h1C, but not of the h1A integrin variant,
up-regulates IGF-II mRNA and protein levels. IGF-II in turn
activates h1C and increases cell adhesion to Laminin-1. The me-
chanism through which h1C increases IGF-II–mediated cell
adhesion to Laminin-1 is controlled by activation of the Gab1/
Shp2/PI3K pathway.
IGF-II expression has been shown to be up-regulated by prolactin
in breast cells (47) and down-regulated by the protein phosphatase
PTEN in hepatoma cells (48), but regulation of IGF-II levels by
integrins has never been reported. Although a role for integrins in
regulating the expression of growth factors is known (49), our
findings provide the first example directly correlating the autocrine
production of a growth factor by an integrin with activation of the
same integrin.
Figure 7. Shp2 is required for IGF-I stimulated adhesion to laminin-1 of h1C expressing cells. Shp2
/ and wt-Shp2 3T3 cells were transiently transfected with
vector alone or human h1A or h1C. Cells were detached and seeded on BSA or laminin-1-coated (A) or fibronectin-coated (B ) 96-well plates at 37jC for 2 hours in the
presence or absence of IGF-I and stained with h-gal. Cell adhesion was expressed as percentage of attached cells transfected with vector alone in the presence
of IGF-I, set at 100. A, differences in cell adhesion to laminin-1 between pBJ-h1A or pBJ-h1C cDNA transfected wt-Shp2 expressing 3T3 cells in the presence or
absence of IGF-I are statistically significant. **, P V 0.0008; *, P V 0.023. Experiments were repeated at least twice with similar results. Columns, mean; bars, SE.
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Figure 8. PI3K activation supports cell adhesion to laminin-1 of h1C-expressing cells. A, h1C-CHO (C11) and h1A-CHO (A11) cells were cultured in the absence of
tetracycline. After 36 hours, cells were incubated for 30 minutes at 37jC in the presence or absence of wortmannin (WM) or the solvent alone (Me2SO). Cells were
lysed, and proteins were immunoblotted with an antibody to phospho-Akt or to Akt. B, h1C-CHO (C11) and h1A-CHO (A11) cells were cultured in the absence of
tetracycline. After 36 hours, 2.5  104 cells were labeled with 51Cr-sodium chromate and incubated for 30 minutes at 37jC in the presence or absence of wortmannin at
different concentrations or the solvent alone (Me2SO) and then allowed to adhere to laminin-1 or BSA (100 Ag/mL) for 2 hours at 37jC. The addition of 50 nmol/L
wortmannin resulted in a statistically significant decrease in h1C-mediated cell adhesion to laminin-1. *, P V 0.001. C, h1A-CHO cells (A11) were transiently transfected
with pCMV-h-gal along with a vector alone, a myc -tagged wild-type PI3K p110 catalytic subunit (myc-p110 wt), or a myc -tagged constitutively active PI3K p110 catalytic
subunit (myc-p110 c.a.). After 48 hours in the absence of tetracycline in culture medium, the cells were assayed for their ability to adhere to laminin-1 (100 Ag/mL) for 2
hours at 37jC. Attached cells were fixed, stained for h-gal, and counted. Attachment of myc-p110 c.a.–transfected cells was expressed as percentage (average and
SD) of the number of cells transfected with vector alone, set at 100. The transfection of myc-p110 c.a. resulted in a statistically significant increase in h1A-mediated cell
adhesion to laminin-1. *, P V 0.001. The experiments were repeated at least twice with two different clones for each h1 integrin variant with similar results. Columns,
mean; bars, SD. Results using representative clones. Protein expression for each transfected cDNAs was confirmed by immunoblotting (bottom ). D, h1A-GD25 (clone
A1) and h1-null GD25 cells were transiently transfected with 1 Ag pCMV-h-gal and 1 Ag of either vector alone or myc-p110 c.a. and assayed for their ability to adhere to
laminin-1 (50 Ag/mL). After adhesion for 3 hours at 37jC, the cells attached were fixed and stained for h-gal as described in Materials and Methods. h1A-GD25
transiently transfected cells were preincubated for 1 hour on ice with either P4C10 (1:200) or 1C10 mAb (1:200) and allowed to adhere to laminin-1 in the presence of
the antibodies. The expression of the transfected cDNAs was confirmed by immunoblotting with a mAb to c-myc (2 Ag/mL). mAb to tubulin (a-tubulin ) was used to
control for protein loading (bottom ). Columns, mean; bars, SD. , h1-null GD25; h1A-GD25 (A1).
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The cross-talk between IGF-II and h1 integrins is likely to
affect prostate cancer progression (31). h1C appears to be
required to maintain a normal phenotype. Specifically, h1C
supports IGF-mediated cell adhesion to Laminin-1 via activation
of the Gab1/Shp2 pathway, prevents IGF-I– or -II– mediated cell
proliferation (31), and up-regulates IGF-II mRNA and protein
levels. The resulting effect is a firmly attached cell that does not
proliferate. In prostate cancer, the h1C integrin and Gab1 are
down-regulated (40, 50) and cannot provide self-sustained IGF -
dependent cell adhesion. Reexpression of h1C in PC3 cells
increases IGF-II levels and cell adhesion to Laminin-1 (as shown
in this study), but inhibits IGF-dependent cell proliferation (31).
Therefore, failure to express h1C results in reduced IGF-II levels
and cell attachment, but allows increased cell proliferation in
response to exogenous IGF.
Although the tumor microenvironment provides a compensatory
mechanism that may replenish cells with IGFs, controversial results
have been published concerning IGF-II levels detected in prostate
cancer. Indeed, IGF-II mRNA and protein levels have been shown
to be increased (51, 52) or reduced (53) as a consequence of
complete deregulation of the IGF axis in prostate cancer
progression. A longitudinal study on aging population showed
that high IGF-I and low IGF-II are independently associated with
increased risk of prostate cancer, which suggests that IGF-II may
inhibit both growth and development of prostate cancer (54).
Cohen et al. showed that IGF-II levels were not different among
subjects with cancer and normal controls (55). However, it is clear
that either released from a tumor cell or from a stromal cell,
ultimately IGF-II stimulates a response that is selectively regulated
by integrins. It remains to be established whether locally released
IGF-II in response to h1C expression is produced as a complex that
differs from the plasma IGF-II form and that may be accessible to
the cells in different forms.
IGF-II controls h1C-mediated cell adhesion to Laminin-1 via
activation of PI3K. We have previously shown that h1C binds Gab1
but not IGF-IR, whereas h1A forms a complex with IGF-IR and
IRS-1 (31). Gab1 is an adaptor molecule which functions
downstream to IGF-IR (56) and binds proteins like Shp2 (57).
Shp2 is a widely expressed nontransmembrane tyrosine phospha-
tase (58). Indeed, h1C expression is necessary to recruit Shp2 to
IGF-IR (Fig. 6). Zhang et al. have shown that IGF-I-stimulated
activation of PI3K is inhibited in Shp2-null cells (38). Similarly, Wu
et al. have shown that Shp2 is a positive regulator of PI3K pathway
activation (59). Thus, Gab1 and Shp2 play an essential role in
IGF-I-mediated PI3K activation. Because Shp2 mediates IGF
stimulation of PI3K (38), we investigated whether PI3K activation
was the limiting step in cell adhesion to Laminin-1. Our data show
that the h1A/IGF-IR complex promotes IGF-mediated cell prolifer-
ation but not cell adhesion to Laminin-1 and, compared with
h1C, causes a mild activation of AKT phosphorylation, a
downstream target of PI3K, in response to IGF (31). Indeed, we
show here that expression of a constitutively active form of the
PI3K in h1A-expressing cells is able to increase cell adhesion to
Laminin-1, in the absence of IGF-II stimulation. These results show
that the PI3K is the downstream intracellular signaling molecule
that controls h1- and IGF-II–mediated cell adhesion to Laminin-1,
and its activation is a limiting step in h1A-expressing cells. These
findings also suggest that PI3K increases h1C ability to bind
Laminin-1, in line with previous reports showing an involvement of
the PI3K signaling pathway in regulating integrin binding capacity
to ECM ligands by growth factor receptors (16, 17).
In conclusion, the concurrent local loss of h1C integrin, of its
ligand Laminin-1 and of IGF-II in the tumor microenvironment may
promote prostate cancer cell invasion and metastasis by reducing
cancer cell adhesive properties. It is, therefore, conceivable that
reexpression ofh1C will be sufficient to revert a neoplastic phenotype
to a nonproliferative and highly adherent normal phenotype.
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